Sugi Predict

Sugi Predict / Compounds / SCHEMBL20100982

SCHEMBL20100982

SCHEMBL20100982

COc1cc(-c2cncc(N[C@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)ccc1O

nearest known ligand 0.82

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 16/20 0.82
▸ RET P07949 1/20 0.58
▸ PDGFRB P09619 1/20 0.58
▸ KIT P10721 1/20 0.58
▸ SRC P12931 1/20 0.58
▸ PDGFRA P16234 1/20 0.58
▸ FLT1 P17948 1/20 0.58
▸ FLT4 P35916 1/20 0.58
▸ KDR P35968 1/20 0.58
▸ FRK P42685 1/20 0.58
▸ DDR1 Q08345 1/20 0.58
▸ LDHA P00338 1/20 0.49
▸ LDHB P07195 1/20 0.49
▸ PFKFB3 Q16875 1/20 0.43
▸ BRAF P15056 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13339903 1.00 CSF1R (0.82) CSF1RRETPDGFRBKITSRC
SCHEMBL20100986 1.00 CSF1R (0.82) CSF1RRETPDGFRBKITSRC
SCHEMBL13340082 0.94 CSF1R (0.82) CSF1RRETPDGFRBKITSRC
Seralutinib SCHEMBL17324860 0.94 CSF1R (0.72) CSF1RRETPDGFRBKITSRC
Seralutinib SCHEMBL29415597 0.94 CSF1R (0.72) CSF1RRETPDGFRBKITSRC
Seralutinib SCHEMBL18867902 0.94 CSF1R (0.72) CSF1RRETPDGFRBKITSRC
Seralutinib SCHEMBL20100984 0.94 CSF1R (0.72) CSF1RRETPDGFRBKITSRC
Seralutinib SCHEMBL30738060 0.94 CSF1R (0.72) CSF1RRETPDGFRBKITSRC
SCHEMBL17324861 0.93 CSF1R (0.71) CSF1RRETPDGFRBKITSRC
SCHEMBL20100983 0.93 CSF1R (0.71) CSF1RRETPDGFRBKITSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11364238-B2 Combination therapy for treating pulmonary hypertension PULMOKINE, INC. (US) 2022-06-21 — — US disclosed
US-20210038510-A1 FORMULATIONS OF KINASE INHIBITORS AND PROSTANOIDS PULMOKINE, INC. 2021-02-11 — — US disclosed
WO-2019157337-A1 FORMULATIONS OF KINASE INHIBITORS AND PROSTANOIDS PULMOKINE, INC. (US) 2019-08-15 — — WO disclosed
US-10231966-B2 Combination therapy for treating pulmonary hypertension PULMOKINE, INC. (US) 2019-03-19 — — US disclosed
WO-2018081567-A1 COMBINATION THERAPY FOR TREATING PULMONARY HYPERTENSION PULMOKINE, INC. (US) 2018-05-03 — — WO disclosed
US-20180117039-A1 COMBINATION THERAPY FOR TREATING PULMONARY HYPERTENSION PULMOKINE, INC. 2018-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10231966-B2 Combination therapy for treating pulmonary hypertension EDNRB, EDNRA, PDGFRB CSF1R 551/4885RET 236/4885PDGFRB 3/4885
US-20210038510-A1 FORMULATIONS OF KINASE INHIBITORS AND PROSTANOIDS PTGIR, PTGIS, PTGFR CSF1R 1178/4885RET 546/4885PDGFRB 5/4885
US-20180117039-A1 COMBINATION THERAPY FOR TREATING PULMONARY HYPERTENSION EDNRB, EDNRA, PDGFRB CSF1R 551/4885RET 236/4885PDGFRB 3/4885
US-11364238-B2 Combination therapy for treating pulmonary hypertension EDNRB, EDNRA, PDGFRB CSF1R 551/4885RET 236/4885PDGFRB 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.